Open AccessAtheroembolic disease following administration of tissue plasminogen activator (TPA)
Author(s) -
Aggarwal Kul,
Tjahja Imam E.
Publication year - 1996
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.4960191114
Subject(s) - medicine , thrombolysis , tissue plasminogen activator , disease , myocardial infarction , plasminogen activator , intensive care medicine , thromboembolic disease , cardiology , thrombosis
Atheroembolic disease is an uncommon condition with many interesting manifestations and has been reported following various procedures. Its occurrence following thrombolytic therapy is extremely rare, with only a few case reports in the literature. However, with the widespread application of thrombolysis in patients with acute myocardial infarction, its incidence is likely to increase and therefore this entity needs to be recognized. Early recognition of the illness may help avoid further expensive and unnecessary investigations. We report two cases of atheroembolic disease following the administration of human recombinant tissue plasminogen activator (TPA).